Gene Rearrangement Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Gene Rearrangement clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 2

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

Intrahepatic CholangiocarcinomaFGFR2 Gene RearrangementFGFR2 Gene Mutation
Mehmet Akce38 enrolled1 locationNCT06728410
Recruiting
Phase 2

REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis

NSCLCBrain MetastasesROS1 Gene Rearrangement
MedSIR20 enrolled16 locationsNCT06315010
Recruiting
Phase 1

Study of SGR-1505 in Mature B-Cell Neoplasms

High-grade B-cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+23 more
Schrödinger, Inc.98 enrolled36 locationsNCT05544019
Recruiting
Phase 2

Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

Advanced CholangiocarcinomaFGFR2 FusionsGene Rearrangement
Taiho Oncology, Inc.120 enrolled65 locationsNCT05727176
Recruiting

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Breast CancerOvarian CancerEndometrial Cancer+40 more
Massive Bio, Inc.50,000 enrolled68 locationsNCT03452774
Recruiting
Not Applicable

Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC

Non-small Cell Lung CancerALK Gene Rearrangement Positive
Groupe Francais De Pneumo-Cancerologie100 enrolled46 locationsNCT05122806
Recruiting
Phase 2

Phase 2 Trial of BN104 as Post-HSCT Maintenance in Acute Leukemia

Acute LeukemiaMenin InhibitorsPost Hematopoietic Stem Cell Transplantation+4 more
The First Affiliated Hospital of Soochow University60 enrolled1 locationNCT07101497
Recruiting
Phase 2

Study of Crizotinib for ROS1 and MET Activated Lung Cancer

Stage IV Non-Small Cell Lung CancerMET AmplificationNon-squamous Non-small Cell Lung Cancer+2 more
University Health Network, Toronto50 enrolled1 locationNCT04084717